News-Yaohai Biopharmaceutical Co., Ltd.

News

Harnessing the Power of Fed-batch Fermentation Strategy

Sep 20, 2024

Pichia pastoris is widely used in the production of various heterologous proteins. The High-Cell-Density Fermentation (HCDF) technology, implemented through Fed-Batch feeding, has successfully achieved large-scale production of biopharmaceuticals and...

Conquering Hepatitis B with Yaohai
Sep 19, 2024
The World Health Organization (WHO) reports that annually, 1.5 million new cases of chronic hepatitis B infection emerge, affecting 296 million individuals globally. Hepatitis B is the disease that causes the most deaths after COVID-19. Therefore, we...
Read More
Comparative Analysis of Yeast and E. coli in Release Testing
Sep 18, 2024
In the field of biopharmaceuticals, Escherichia coli (E. coli) and yeast are two widely used microbial expression systems that have addressed significant challenges such as industrialization and batch-to-batch stability of biological products. Levera...
Read More
Do You Know the Groundbreaking Advancement in Insulin Technology?
Sep 14, 2024
Recombinant human insulin is a paradigmatic case of the mass production of genetically engineered drugs and a crucial application for microbial expression. Since its discovery a century ago, insulin medications have undergone continuous advancements,...
Read More
The Application of VLPs in Human and Veterinary Vaccines
Sep 13, 2024
Last week, we briefly introduced the features, mechanisms of action (MoA), and expression systems of VLPs (Virus-like Particles). VLPs are viral structural proteins that do not contain viral genetic material. Besides, their advantages include nanosca...
Read More
VLPs and Its Manufacturing Process
Sep 12, 2024
Virus-like Particles (VLPs) are unique biomaterials that have similar structures to viruses but essentially do not contain viral genetic material such as DNA or RNA. Therefore, VLPs wouldn't lead to infections in the human body. Due to this character...
Read More
Methods to Improve the Yield of pDNA
Sep 11, 2024
The production of plasmid DNA (pDNA) relies on genetic recombination, which involves connecting the target gene and other elements to form a covalently closed circular structure. High cell-density fermentation of Escherichia coli and purification are...
Read More
Congratulations to Yaohai’s CDMO Client
Aug 15, 2024
Good news! Northland Biotech's Naked Plasmid NL003 BLA was accepted by NMPA On July 16 2024, the valued client of Yaohai Bio-Pharma, Beijing Northland Biotechnology Co., Ltd. (Northland), announced that its independently developed Category 1 new th...
Read More
Yaohai Bio-Pharma Passed EU QP Audit and Attains ISO Triple Certification
May 08, 2024
Good news! Yaohai Bio-Pharma has recently passed the on-site audit by the European Union Qualified Person (QP) for the GMP quality system and production site. Additionally, it has cleared the initial certification audits for ISO9001 Quality Managemen...
Read More
WORLD VACCINE CONGRESS Washington
Apr 08, 2024
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meetings of their kind across the globe. Following a record attendance in 2023 of 3000+ attendees,...
Read More